Application Information

Application Number : 2025/001030

Application Date : 19-10-2018

Application Type : EPC Fasikül

Grant Number : 2025-GE-61273

Grant Date : 30-01-2025

Registration Number : 2025 001030

Registration Date : 2025-02-21

Protection Type : Patent

European Patent Publication Number (B1) : EP3697818B1

European Patent Application Number : EP18804720.3

Applicants

Person No	Name	Address
7590940	F. HOFFMANN-LA ROCHE AG	Grenzacherstrasse 124, CH-4070 Basel İSVİÇRE

Inventors

Person No	Name	Address
7816458	Michael WENGER	C/O F. HOFFMANN-LA ROCHE AG GRENZACHERSTRASSE 124 BASEL 4070 İSVİÇRE
7816460	Chin-Yu LIN	C/O GENENTECH INC. 1 DNA WAY SOUTH SAN FRANCISCO, CA 94080-4990 A.B.D.
7816459	Mehrdad MOBASHER	C/O CORVUS PHARMACEUTICALS INC. 863 MITTEN ROAD, SUITE 102 BURLINGAME, CA 94010 A.B.D.

Invention Information

Name Of Invention	CD20 pozitif b hücreli lenfomanın obinutuzumab ile tedavisi.
Summary Of Invention	Mevcut açıklama, obinutuzumabın uygulama hızı ile ilgilidir.

Attorney Information

Name	ASLI BAYGÜZ DERİŞ PATENT VE MARKA ACENTALIĞI A.Ş.
Address	İnebolu Sok. Deriş Patent Binası No:5 Kabataş/ Setüstü 80040/ İSTANBUL

Priority Information

Date of Priority	Priority Number	Country of Priority
19-10-2017	US 201762574297P	US

Classes of The Invention

Patent Application Procedures

Date	Date of Notification	Operation	Document
	07-02-2025	Şekli Kontrol Yapıldı. Başvuru / İstem / Fasikül Onaylandı.
29-01-2025		EPO'dan Gelen Patent Fasikül

Publications

Publication Date	Description
21-02-2025	Avrupa Patent Fasiküllerinin İlanı

Payment Dates

Row	Year	Payment Date	Amount Paid (₺)